The Firestone Institute for Respiratory Health (FIRH) is based out of St. Joseph's Healthcare in Hamilton, Ontario, Canada and is affiliated with McMaster University. Clinical, research and educational activities are integrated and largely collaborative within the FIRH. The intent of this institute is to provide optimal patient care through clinical practice, translational research and the training of health care professionals.
Drs. John Bienenstock and Paul Forsythe investigate the effects that gut bacteria have on the brain.
Dr. Manali Mukherjee, one of our post-doctoral fellows, won the best poster and abstract award in the session on Autoimmune Mechanisms at the European Academy of Allergy and Clinical Immunology Congress which took place in Helsinki, Finland from June 17-21, 2017. Congratulations Dr. Mukherjee!
Dr.'s Nathan Hambly, Martin Kolb, Mark Inman, and Ciaran Scallan participated in the 2017 Phyllis Gretzky Memorial Golf Classic in support of critical lung health research, sponsored by The Lung Association.
Delaying the introduction of potentially allergenic foods until after a baby's first year may increase the likelihood of a food allergy later on, according to new findings from the Canadian Healthy Infant Longitudinal Development (CHILD) Study.
The research, published in Pediatric Allergy and Immunology, found that infants who avoided cow's milk products, egg and peanut during the first year of life were more likely to be sensitized to these foods at age one.
"Food sensitization early in life is associated with an increased risk of wheeze, asthma, eczema and allergic rhinitis in later childhood," said Dr. Malcolm Sears, co-director of the CHILD Study and a professor of medicine at McMaster University.
New research led by Dr. Parameswaran Nair has found a biologic that may reduce the need of steroid-based medications for patients with severe asthma - improving their quality of life.
Many patients who suffer from severe asthma take steroid-based medications – such as prednisone – to control their symptoms. But these types of medications carry with them a risk of long-term side effects, such as headaches, nausea, sleep problems and weight gain. This new trial found that giving patients with severe asthma a biologic called Benralizumab reduced their use of steroid-based medications by up to 75%.